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Abstract
Background. Maternal polycystic ovary syndrome (PCOS) has been proposed as a model for
investigating the role of prenatal androgen exposure in the development of neuropsychiatric
disorders. However, women with PCOS are at higher risk of developing psychiatric conditions
and previous studies are likely confounded by genetic influences.
Methods. A Swedish nationwide register-based cohort study was conducted to disentangle the
influence of prenatal androgen exposure from familial confounding in the association between
maternal PCOS and offspring attention-deficit/hyperactivity disorder (ADHD), autism spec-
trum disorders (ASD), and Tourette’s disorder and chronic tic disorders (TD/CTD). PCOS-
exposed offspring (n = 21 280) were compared with unrelated PCOS-unexposed offspring
(n = 200 816) and PCOS-unexposed cousins (n = 17 295). Associations were estimated with
stratified Cox regression models.
Results. PCOS-exposed offspring had increased risk of being diagnosed with ADHD, ASD,
and TD/CTD compared with unrelated PCOS-unexposed offspring. Associations were stron-
ger in girls for ADHD and ASD but not TD/CTD [ADHD: adjusted hazard ratio (aHR) = 1.61
(95% confidence interval (CI) 1.31–1.99), ASD: aHR = 2.02 (95% CI 1.45–2.82)] than boys
[ADHD: aHR = 1.37 (95% CI 1.19–1.57), ASD: aHR = 1.46 (95% CI 1.21–1.76)]. For ADHD
and ASD, aHRs for girls were stronger when compared with PCOS-unexposed cousins, but
slightly attenuated for boys.
Conclusions. Estimates were similar when accounting for familial confounding (i.e. genetics
and environmental factors shared by cousins) and stronger in girls for ADHD and ASD,
potentially indicating a differential influence of prenatal androgen exposure v. genetic factors.
These results strengthen evidence for a potential causal influence of prenatal androgen expos-
ure on the development of male-predominant neuropsychiatric disorders in female offspring
of women with PCOS.
Introduction
Prenatal androgen exposure has been hypothesized to be associated with the development of
neuropsychiatric disorders including autism spectrum disorders (ASD) (Baron-Cohen et al.,
2011), attention-deficit/hyperactivity disorder (ADHD) (de Bruin et al., 2006; Baron-Cohen
et al., 2011), and Tourette’s disorder and chronic tic disorders (TD/CTD) (Peterson et al.,
1992; Alexander and Peterson, 2004; Martino et al., 2013). Additionally, some psychiatric dis-
orders show a response to treatment with anti-androgens, such as TD/CTD (Peterson et al.,
1994, 1998), potentially implicating altered androgenic pathways in their etiology.
Polycystic ovary syndrome (PCOS) is the most common endocrine disorder affecting
women of reproductive age (Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus
Workshop Group, 2004). The most prominent feature of PCOS is hyperandrogenism,
characterized by elevated testosterone levels in serum and an
increased testosterone to sex hormone-binding globulin ratio,
which persists throughout a woman’s reproductive years
(Goodarzi et al., 2011). Previous studies have reported signifi-
cantly higher levels of androgens throughout the pregnancies of
women with PCOS, compared with pregnancies of women with-
out PCOS (Sir-Petermann et al., 2002; Anderson et al., 2010;
Barry et al., 2010; Maliqueo et al., 2013).
Studies have therefore utilized maternal PCOS as a model of
offspring exposure to elevated levels of prenatal androgens,
reporting that the children of women with PCOS are at increased
risk of both ASD and ADHD (Palomba et al., 2012; Kosidou et al.,
2016, 2017; Cherskov et al., 2018).
However, women with PCOS themselves have an elevated
prevalence of a range of psychiatric disorders comparedwith women
without PCOS, including ASD and ADHD (Ingudomnukul et al.,
2007; Herguner et al., 2015; Cesta et al., 2016; Cherskov et al.,
2018). Because these disorders are moderate to highly heritable
(Posthuma and Polderman, 2013; Mataix-Cols et al., 2015), it is
possible that the association between maternal PCOS and offspring
neuropsychiatric disorders is confounded by shared genetic influ-
ences. Furthermore, some familial environmental factors associated
with having received a diagnosis of maternal PCOS (e.g. access to
health care, healthcare seeking behavior) may also influence
whether the child receives a neuropsychiatric diagnosis and there-
fore may confound the association. Hence, further investigation is
needed to disaggregate the influence of prenatal androgen exposure
from familial confounding (i.e. genetic and/or environmental
factors).
The first aim of this study was to measure, in the general popu-
lation, the association between maternal PCOS and offspring
neuropsychiatric disorders where prenatal androgen levels and/
or altered androgen function have been implicated in their eti-
ology. The second aim was to determine whether these associa-
tions were sensitive to familial confounding by comparing the
risk of these same neuropsychiatric disorders in the offspring of
siblings of women with PCOS. To this end, we compared cousins
who differ in their prenatal androgen exposure, but share 12.5% of
segregated genes and environmental factors shared by cousins
that make them similar (D’Onofrio et al., 2013). If the increased
risk for psychiatric disorders in the offspring of women with
PCOS is mainly driven by familial factors, we would expect atte-
nuated hazard ratios (HR) in the analysis which account for
familial factors. However, if familial factors are not driving the
findings (i.e. indicating a possible causal effect of prenatal andro-
gen exposure), then the risk estimates for neuropsychiatric disor-
ders should be similar when PCOS-exposed offspring are
compared with PCOS-unexposed unrelated and related offspring.
Notably, rodent models of prenatal androgen exposure have
measured anxiety-like behavior in female offspring, and to a lesser
extent in the male offspring, attributable to changes in hormone
receptor expression in the amygdala (Hu et al., 2015). Therefore,
the third aim was to assess if the associations in the PCOS-exposed
v. PCOS-unexposed offspring differed by sex.
Methods
Data sources
Using the unique personal identification number assigned to each
individual in Sweden at birth or at immigration, several nationwide
longitudinal registers containing health and sociodemographic data
until 31 December 2013 were linked (see online Supplementary
material for more details), including the Swedish Medical Birth
Register (MBR), National Patient Register (NPR), Prescribed
Drug Register (PDR), Multi-Generation Register (MGR), Total
Population Register (TPR), Migration Register, and the Cause of
Death Register (CDR).
Study population and exposure classification
Women who had delivered at least one child were identified
through the MGR. The first diagnostic criteria for PCOS were
established in 1990 (Rotterdam ESHRE/ASRM-Sponsored PCOS
Consensus Workshop Group, 2004). Those women with PCOS
were identified by having at least one PCOS International
Classification of Diseases (ICD) code (ICD-9: 256E; ICD-10:
E28.2) recorded in the MBR or in the NPR after the age of 13
and between 1990 and 2013. Women with a concurrent diagnosed
condition that could cause symptoms similar to PCOS were
excluded to ensure specificity (see online Supplementary
Material for ICD codes). This yielded a total of 12 955 mothers
with PCOS. Time of PCOS diagnosis (before or after delivery)
was not taken into account, since elevated testosterone levels
have been reported to be present throughout life in women
with PCOS (Pinola et al., 2015). Each mother with PCOS was
then matched on her birth year and county of residence within
the year of diagnosis to 10 comparison mothers without a
PCOS diagnosis randomly selected from the general population.
Last, all full brothers (n = 4467) and sisters (n = 7404) of
women with PCOS with children were identified from the MGR.
Using the MGR, offspring born to mothers with PCOS
(PCOS-exposed), matched unaffected mothers (PCOS-unexposed),
and full siblings were identified (PCOS-unexposed cousins). All
offspring from each mother were included. Offspring were
excluded if they were born outside of Sweden, adopted, stillborn
or died on the day of birth, or had congenital malformations.
This yielded a total of 20 988 PCOS-exposed offspring, 200 816
PCOS-unexposed offspring from the general population, and
17 295 PCOS-unexposed cousins (Fig. 1). Offspring were born
between 1973 and 2013, leading to an age range of 0–40 years
at the end of follow-up.
Outcome classification
ADHD – Individuals with either a diagnosis of ADHD in the
NPR (ICD-9: 314; ICD-10: F90) or with a filled prescription of
ADHD medication in the PDR [methylphenidate (Anatomical
Therapeutic Chemical [ATC] classification = N06BA04); amphet-
amine [ATC =N06BA01]; dexamphetamine [ATC =N06BA02];
atomoxetine [ATC = N06BA09]; or lisdexamfetamine [ATC =
N06BA12]] after age 3 were considered to have a diagnosis of
ADHD. The date of diagnosis was defined as the date of the first
diagnosis or first prescription of ADHD medication, whichever
came first (Chen et al., 2017).
ASD – Individuals were identified as having ASD if they had at
least one registered code in the NPR (ICD-9: 299 or ICD-10: F84),
received after the age of 1.
TD/CTD – Individuals with a diagnosis of TD/CTD after
3 years of age were identified using a previously validated algorithm
based on ICD codes (ICD-9: 306.2, 307C; ICD-10: F95), shown to
have excellent positive predictive value when compared with clin-
ical records (Ruck et al., 2015).
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Covariates
Highest attained maternal education level was used as a proxy for
offspring socioeconomic status. Maternal and paternal lifetime
history of psychiatric disorders was determined by any recorded
psychiatric diagnosis in the NPR. Region of birth (Nordic/
non-Nordic) was extracted from the TPR. Offspring sex and
year of birth, as well as maternal age at the offspring’s birth,
were extracted from the MBR.
Statistical analysis
Offspring were followed from the age when they were eligible to
receive a diagnosis of the respective psychiatric conditions to
the date of diagnosis of the neuropsychiatric disorder of interest,
death, emigration, or end of follow-up (31 December 2013),
whichever came first. Associations between maternal PCOS and
offspring neuropsychiatric disorders in the general population
were estimated as HR with 95% confidence intervals (CI) using
stratified Cox regression models with attained age as the under-
lying time scale. Each psychiatric disorder was modeled separately
in both crude and adjusted models. In addition to the maternal
matching criteria (maternal birth year and county of residence
within the year of PCOS diagnosis), potential confounding was
addressed in the fully adjusted models by controlling for offspring
sex and year of birth, maternal age at child’s birth, maternal edu-
cation, maternal region of birth, and maternal and paternal life-
time history of psychiatric disorders. Robust standard errors
were used to account for dependence between observations
since several children from the same family were included in
the study population. In order to assess if the associations
remained after adjusting for familial confounding, the analyses
were repeated in the sample with PCOS-unexposed cousins in a
similar manner. Cousins share on average 12.5% of the segregat-
ing genes. Furthermore, some environmental risk factors may be
shared between cousins as well (e.g. family background character-
istics such as socioeconomic position). Therefore, comparing
differentially exposed cousins controls for both measured covari-
ates included in the model, and reduces confounding from
unmeasured factors (both genetic and environmental) shared
between cousins (D’Onofrio et al., 2013).
The analysis was conducted first for all offspring combined,
and then stratified by offspring sex. We performed Wald tests
to formally test if the associations statistically differed by offspring
sex.
Sensitivity analyses
Year of PCOS diagnosis – Diagnostic criteria for PCOS changed
over the study period (Rotterdam ESHRE/ASRM-Sponsored
PCOS Consensus Workshop Group, 2004). Therefore, a stratified
analysis of offspring born to women with their first PCOS diagno-
ses between 1990 and 2003 and between 2004 and 2013 was
conducted.
Offspring from brothers v. sisters of women with PCOS –
Depending on the diagnostic criteria used, the prevalence of
PCOS varies from 5% to 15% in women of reproductive age
(March et al., 2010). Given that the prevalence of a PCOS diagno-
sis in the NPR is lower than expected (approximately 2%),(Cesta
et al., 2016) and the high heritability of PCOS (60–70%) (Vink
et al., 2006; Cesta et al., 2017), it is highly likely that there are sis-
ters of women with PCOS misclassified as ‘unaffected’ because
they have not received a diagnosis of PCOS. The downstream
implication of this is that their offspring would be misclassified
as unexposed cousins in the primary analysis. However, the risk
of misclassification is lower for the offspring of brothers of
women with PCOS. Therefore, we performed the analysis for
the unexposed cousins born to brothers and sisters of women
with PCOS separately.
Outpatient coverage – The NPR includes only diagnoses made
in inpatient care until 2001 when outpatient specialist care was
added to the register. Therefore, if an individual received a diag-
nosis in outpatient care before 2001, they would only be identified
as a case in this study if there was a subsequent diagnosis after
Fig. 1. Flowchart of inclusion and exclusion criteria of study population. PCOS, polycystic ovary syndrome.
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2001. This will lead to either a misclassification of the outcome, or
left censoring of incident cases before 2001, thereby leading to a
longer time to event. Hence, a sensitivity analysis was conducted
where children were included only if their outpatient care was
covered in the NPR. The minimum age for diagnosis for each
of the outcomes varied and therefore different years of birth
were used for each analysis: the analysis for ADHD included chil-
dren born from 1998, for ASD children born from 2000, and for
TD/CTD from 1998.
All analyses were performed using Stata statistical software ver-
sion 14.0 (Stata Corps, Texas, USA).
Results
Descriptive characteristics
Descriptive characteristics of the study population by category of
exposure are presented in Table 1. PCOS-exposed offspring were
more often born to mothers who were slightly older and who
had a lifetime history of psychiatric diagnoses, compared with
both categories of PCOS-unexposed offspring. ASD, ADHD, and
TD/CTD were more prevalent in PCOS-exposed offspring com-
pared with PCOS-unexposed offspring born to unrelated mothers
from the general population, but prevalence estimates were similar
to their PCOS-unexposed cousins. The mean age (±standard devi-
ation) of the offspring at the end of follow-up was 9.2 ± 7.6 years.
Main analyses
PCOS-exposed offspring had crude HRs ranging from 1.61 to 1.90
and adjusted HRs (aHR) from 1.46 to 1.60 for being diagnosed
with ADHD, ASD, or TD/CTD (Table 2), compared with
PCOS-unexposed unrelated offspring. Similar estimates were
found when familial factors were controlled for by comparing
PCOS-exposed offspring with their unexposed cousins, albeit
with wider CIs due to the smaller sample sizes (Table 2).
Figure 2 and Table 2 show the HRs of the analysis stratified by
offspring sex. Associations were stronger in girls than in boys
for both ADHD (aHR = 1.61 v. aHR = 1.37) and ASD (aHR =
2.02 v. aHR = 1.46) when compared with PCOS-unexposed unre-
lated offspring from the general population. Restricting the com-
parison group to PCOS-unexposed cousins led to a slight
attenuation of the aHRs for ADHD and ASD in boys, but a slight
increase in the aHR in girls. The difference between boys and girls
was statistically significant for ADHD when PCOS-exposed off-
spring were compared with their unexposed cousins ( p-value:
0.038), but not for any other association.
Risk of receiving a diagnosis for TD/CTD was similar between
girls and boys (aHR = 1.51 v. aHR = 1.54) with overlapping CIs.
When compared with PCOS-unexposed cousins, the aHR
increased for boys, although with much wider CIs around the esti-
mate. For girls, it was not possible to fit a fully adjusted model
when comparing to PCOS-unexposed cousins as the number of
TD/CTD cases was too few.
Kaplan–Meier curves are presented in online Supplementary
Fig. S1, and Table S1 presents the follow-up time in person years
among exposed and unexposed, shown separately for each outcome.
Sensitivity analyses
Year of PCOS diagnosis – Of the mothers with PCOS, 25%
received their first PCOS diagnosis between 1990 and 2003, and
they bore 28% of the PCOS-exposed offspring in this cohort.
Table 3 shows the results of the analysis stratified by the years
of PCOS diagnosis for ADHD and ASD only, as the number of
cases in each of the strata for TD/CTD were too few. The esti-
mates for both time periods were largely comparable with those
of the primary analysis.
Offspring of brothers v. sisters of women with PCOS – There
was no clear difference in estimates calculated separately for off-
spring of brothers (n = 8584) and sisters (n = 9454) of women
with PCOS (online Supplementary Table S2). These results were
also similar to the estimates reported in the primary analysis.
Outpatient coverage – Estimates calculated for children with
follow-up in outpatient care were similar to those in the main
analysis (online Supplementary Table S3).
Discussion
In this national register-based study of mothers and their off-
spring, we found that children born to mothers with PCOS had
a higher risk of being diagnosed with ADHD, ASD, and TD/
CTD, compared with children born to mothers from the general
population without PCOS. For ADHD and ASD, the comparison
to PCOS-unexposed cousins attenuated the associations in boys
and increased the estimates in girls. This supports the theory of
prenatal androgen exposure influencing the development of
some neuropsychiatric disorders, at least in female offspring,
over and above shared familial factors.
The organizational/activational theory of steroid hormones
posits that prenatal exposure to elevated androgens may cause
permanent alterations (organizational effects) of neural systems
leading to ‘hyper-masculine’ behavioral and cognitive traits,
thereby increasing the risk for the development of neurodevelop-
mental and psychiatric disorders predominantly found in males
such as ADHD, ASD, and TD/CTD (Arnold, 2009; Martino
et al., 2013). For human female fetuses, levels of androgens are
very low throughout gestation, whereas male fetuses have been
shown to have higher levels of testosterone from approximately
the 8th to 24th week of gestation. Evidence from both human
and animal studies supports a larger effect of prenatal androgen
exposure on cognitive and behavioral traits in females (Auyeung
et al., 2013; Wang et al., 2017). Complementary to the results
from our study, prenatal androgen exposure during late preg-
nancy has been found to increase anxiety-like behavior in female
offspring, and to a lesser extent in the male offspring, in a rodent
model (Hu et al., 2015).
Maternal PCOS has been utilized as a model of offspring
exposure to elevated levels of prenatal androgens in previous stud-
ies. Consistent with the findings from our study, Kosidou and col-
leagues reported increased risk for ADHD and ASD in children of
women with PCOS in their case–control studies [from similarly
adjusted models: odds ratio (OR) = 1.42 (95% CI 1.26–1.58),
OR = 1.59 (95% CI 1.34–1.88), respectively] (Kosidou et al.,
2016, 2017). Further adjustment for obstetrical characteristics
did not significantly influence their findings; however, accounting
for obesity and cardiometabolic profiles in the mothers increased
the estimates. It is relevant to note that our study population par-
tially overlaps with those of Kosidou et al. However, the birth
years of the children included in our study extend 11 years before
and 2 years after their study period, yielding at least one-third
more ADHD and ASD PCOS-exposed cases in our analysis.
Further, while parental psychiatric history was accounted for in
the studies by Kosidou et al., they did not attempt to further
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account for the influence of genetic confounding shared by PCOS
and psychiatric disorders (Ingudomnukul et al., 2007; Herguner
et al., 2015; Cesta et al., 2016), or by familial environmental fac-
tors such as health-seeking behavior. When stratified by offspring
sex, the odds for having a diagnosis of ADHD was higher in
females (OR = 1.53 v. 1.37 for male offspring), but the same for
both sexes for ASD diagnoses (Kosidou et al., 2016, 2017).
In line with our findings, Palomba et al. (2012) reported a
higher risk of ASD in daughters, but not in sons, of women
with PCOS (Palomba et al., 2012). However, Cherskov et al.
(2018) reported a higher adjusted risk of ASD in first born sons
and but not daughters of women with PCOS (Cherskov et al.,
2018).
It is difficult to draw causal conclusions based on observational
studies due to the influence of unmeasured confounding.
Genetically informative designs, such as family-based study designs,
can be used to better account for unmeasured confounding of factors
shared in families, such as genetic influences. Sibling comparison
studies are often used, because comparing exposure discordant sib-
lings allows for the adjustment for genetic and environmental factors
shared between siblings (D’Onofrio et al., 2013). However, elevated
testosterone levels are present throughout life in women with
Table 1. Descriptive characteristics of study population
Characteristic
PCOS-exposed
offspring (N = 20 988)
PCOS-unexposed
offspring (unrelated)
(N = 200 816)
PCOS-unexposed
offspring (cousins)
(N = 17 295)
n % n % n %
Sex of offspring
Male 10 779 51.36 102 528 51.06 8940 51.69
Female 10 209 48.64 98 288 48.94 8355 48.31
Child’s year of birth
1973–1984 314 1.5 3317 1.65 817 4.72
1985–1989 539 2.57 6869 3.42 1151 6.66
1990–1994 1333 6.35 16 739 8.34 2059 11.91
1995–1999 2034 9.69 23 402 11.65 2213 12.8
2000–2004 3398 16.19 38 105 18.98 3242 18.75
2005–2009 6397 30.48 57 488 28.63 4284 24.77
2010–2013 6973 33.22 54 896 27.34 3529 20.4
Maternal age at child’s birth (years)
<20 540 2.57 6296 3.14 722 4.17
20–24 3847 18.33 43 570 21.70 4158 24.04
25–29 7108 33.87 74 121 36.91 6086 35.19
30–34 6486 30.90 57 995 28.88 4637 26.81
35+ 3007 14.33 18 834 9.38 1692 9.78
Mother’s region of birth
The Nordic countries 16 595 79.07 167 284 83.30 15 432 89.23
Outside the Nordic countries 4393 20.93 33 532 16.70 1863 10.77
Maternal highest achieved educationa
Primary and secondary education 2152 10.3 19 650 9.85 2019 11.72
Upper secondary education 9087 43.47 88 465 44.33 8267 47.98
Post-secondary/post-graduate education 9664 46.23 91 424 45.82 6945 40.31
Maternal lifetime history of any psychiatric diagnosis 4660 22.2 31 294 15.58 2914 16.85
Paternal lifetime history of any psychiatric diagnosis 2318 11.04 20 898 10.41 1845 10.67
Offspring psychiatric disorders
ADHD 681 3.24 5440 2.71 602 3.48
ASD 256 1.22 1765 0.88 202 1.17
TD/CTD 38 0.18 282 0.14 30 0.17
ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorders; PCOS, polycystic ovary syndrome; TC/CTD, Tourette disorder/chronic tic disorder.
aCategories do not add up to the total number because maternal education is missing for 0.6% of children.
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PCOS (Pinola et al., 2015), and therefore theoretically all of their off-
spring are exposed to elevated androgens in utero. This makes it
impossible to conduct a sibling comparison study, where siblings
need to be discordantly exposed. Therefore, we employed an ‘off-
spring of siblings’ study design where differentially exposed cousins
were used as a comparison group to help account for unmeasured
genetic and environmental factors. Our findings, based on these cou-
sin comparisons, suggest that elevated androgens in utero influence
the development of male-predominant neuropsychiatric disorders in
female offspring over and above the genetic and familial factors asso-
ciated with the maternal psychiatric illness that are comorbid with
PCOS. This suggests that familial confounding does not play a
large role in the findings of previous studies published on this topic.
However, there are some important limitations regarding the
cousin design. First, the cousin comparison design requires
assumptions about equal environmental influences and variability
in measures across cousin types. Although this is the first study to
account for familial factors in association between maternal PCOS
and offspring neuropsychiatric disorders, in comparison with a
sibling comparison design for example, the cousin comparison
captures a smaller fraction of the potential confounding from gen-
etic and environmental influences. The resulting residual genetic
confounding could inflate our estimates of the association, and
the true association between maternal PCOS and offspring psy-
chiatric disorders might be weaker than what we observed.
On the other hand, compared with the prevalence of PCOS in
the general population, PCOS is greatly underrepresented in the
NPR. Therefore, misclassification of PCOS in the mothers is a
possibility which consequently misclassifies the exposure status
of some of the offspring, leading to a possible dilution of the mea-
sured associations. Further, this misclassification bias has the
potential for a higher impact in the analysis between the
PCOS-exposed offspring and their unexposed cousins, as mis-
classification of exposure is likely more frequent in analyses
based on exposure-discordant cousins than in studies based on
the general population. Due to the high heritability of PCOS, sis-
ters of women with PCOS are expected to have higher levels of
PCOS. When there is discordance between PCOS status in sisters,
it is more likely to be due to misclassification than when consid-
ering women from the general population (Frisell et al., 2012).
Therefore, we attempted to capture the degree of bias due to mis-
classification by analyzing cousins born to sisters of women with
PCOS and cousins born to brothers of women with PCOS as two
separate control groups. The results from the sensitivity analysis
did not differ, indicating that it is unlikely that there is exagger-
ated misclassification bias in the cousin comparison analysis.
The diagnostic criteria for PCOS changed over the study period.
The first diagnostic guidelines for PCOS established by the National
Institute of Health in 1990 required the presence of both hyperan-
drogenemia and oligo- and/or anovulation for diagnosis. In 2003,
the Rotterdam diagnostic guidelines were issued and introduced a
third possible criterion – polycystic ovaries (Rotterdam ESHRE/
ASRM-Sponsored PCOS Consensus Workshop Group, 2004). As
only two of the three criteria are required for PCOS diagnosis
under the latter guidelines, there are PCOS phenotypes that do
not include hyperandrogenemia, thereby creating a more heteroge-
neous group of women with PCOS in the later study years.
Therefore, by stratifying the analysis based on year of PCOS diagno-
sis, it is more certain that children born to women with PCOS diag-
nosed between 1990 and 2003 were exposed to higher prenatal
androgen levels. However, findings from this stratified analysis




































































































































































































































































































































































































































































































































































































































































































































































































































































































































































referral bias for PCOS, where women with more complete pheno-
types of PCOS (i.e. with hyperandrogenemia) and higher body
mass index are more likely to seek and receive medical care
(Lizneva et al., 2016), leading to a more homogeneous population
of women diagnosed with PCOS in all years of our study.
Additionally, daughters of women with PCOS have a high like-
lihood of being diagnosed with PCOS, which could account for
the higher rates of psychiatric disorders in this study (Xita and
Tsatsoulis, 2006). However, symptoms of PCOS do not emerge
before puberty and the appearance of a diagnosis in the
Swedish National Registers occurs at a mean age of 28 years
(Cesta et al., 2016). Therefore, due to the young age of the cohort,
it is not possible to identify offspring with a potential PCOS diag-
nosis. Further, by comparing cousins we adjusted for some of the
genetic factors influencing both PCOS and psychiatric disorders.
The main strengths of this study include the use of longitudinal
population-based national register data to assess the association of
maternal PCOS with neuropsychiatric outcomes in the offspring,
and the use of a cousin comparison group to adjust for familial
confounding. Further, this is the first study to assess the risk of
TD/CTD in children of mothers with PCOS, and the first to
include multiple psychiatric outcomes based on clinical diagnoses.
In addition to the limitations of the cousin-design discussed
above and the change in the diagnostic criteria for PCOS, we
did not have actual laboratory data on the androgen status during
pregnancy of mothers with PCOS in this study. As a proxy, we
performed a stratified analysis based on the diagnostic criteria
of PCOS, identified by the year of PCOS diagnosis.
The role of the prenatal period in the etiology of neuropsychi-
atric disorders in children is of considerable research and clinical
interest. Prenatal exposure to androgens has been the subject of
many animal, clinical, and observational studies. Due to the ele-
vated levels of androgens that are characteristic of PCOS, maternal
PCOS has recently been used as a model for measuring the risk of
Fig. 2. aHRs and 95% CIs for the risk of psychiatric disorders in PCOS-exposed and PCOS-unexposed offspring, stratified by sex. ADHD, attention-deficit/hyperactiv-
ity disorder; ASD, autism spectrum disorders; CI, confidence interval; HR, hazard ratio; PCOS, polycystic ovary syndrome; TD/CTD, Tourette’s disorder/chronic tic
disorder. Note: For the TD/CTD analyses for girls, it was not possible to fit a fully adjusted model when comparing to PCOS-unexposed cousins as the number of
cases was too few.
Table 3. Adjusted hazard ratios and 95% CIs for the risk of ADHD and ASD in PCOS-exposed and PCOS-unexposed offspring, by year of maternal PCOS diagnoses
Outcome
PCOS-unexposed offspring (unrelated) PCOS-unexposed offspring (cousins)
n = exposed/unexposed aHR (95% CI) n = exposed/unexposed aHR (95% CI)
ADHD
1990–2003 291/1962 1.56 (1.32–1.84) 291/234 1.35 (0.96–1.89)
2004–2013 390/3479 1.39 (1.20–1.61) 390/368 1.42 (1.03–1.95)
ASD
1990–2003 97/661 1.62 (1.28–2.05) 97/73 1.39 (0.84–2.28)
2004–2013 159/1105 1.54 (1.24–1.90) 159/129 1.57 (1.00–2.47)
Models adjusted for offspring sex and year of birth, maternal age at child’s birth, maternal education, maternal region of birth, and maternal and paternal lifetime history of psychiatric
disorders.
ADHD, attention-deficit/hyperactivity disorder; ASD, autism spectrum disorders; CI, confidence interval; HR, hazard ratio; PCOS, polycystic ovary syndrome.
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elevated prenatal androgen exposure on the development of off-
spring psychiatric disorders. However, the results of these studies
are at risk of being influenced by familial confounding due to the
higher prevalence of psychiatric disorders in women with PCOS.
We used a unique cousin-comparison design – which accounted
for some degree of unmeasured familial confounding – made feas-
ible by the comprehensive Swedish national registers. Our results
add to a growing body of evidence supporting the influence of pre-
natal androgen exposure on the development of male-predominant
neuropsychiatric disorders in children born to women with PCOS,
with potentially differential influence of the prenatal environment
v. genetics depending on the sex of the offspring. However, due
to the limitations of the cousin design, these findings should be
confirmed using other approaches and study designs.
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